

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 22862-0003US1	Application No. 10/598,486
Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant Yu et al.	
		Filing Date August 31, 2006	Group Art Unit 1636

Non-Patent Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
	1	Abiru et al., "Aspirin and NS-398 inhibit hepatocyte growth factor-induced invasiveness of human hepatoma cells," Hepatology, 35:1117-24 (2002)
	2	Ferrandina et al., "Celecoxib modulates the expression of cyclooxygenase-2, Ki67, apoptosis-related marker, and microvessel density in human cervical cancer: a pilot study," Clin. Cancer Res., 9:4324-31 (2003)
	3	Sheng et al., "Inhibition of human colon cancer cell growth by selective inhibition of cyclooxygenase-2," J. Clin. Invest., 99:2254-59 (1997)
	4	Zitvogel et al., "Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell-1 associated cytokines," J. Exp. Med., 183:87-97 (1996)

Examiner Signature /Amy Juedes/	Date Considered 01/15/2009
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Disclosure Form (PTO-1449)

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /AJ/